Palliative treatment of intestinal obstruction in patients with gynecologic malignancies — single center experience
, 1, 1, 1, 1, 1, 1
Abstract
Objectives: One of the common symptoms in patients with advanced gynecologic tumors is intestinal obstruction. Palliative management may include pharmacological treatment, stenting as well as surgical removal of obstruction cause. Selection of appropriate treatment should be based on careful and individual assessment of advantages, disadvantages and possible complications. The aim of the study was to analyze the effectiveness of non-invasive treatment in patients with gynecologic malignancies suffering from intestinal obstruction.
Material and methods: It was a retrospective analysis of factors associated with primary non-invasive intestinal obstruction treatment effectiveness. Data were collected from medical records of 17 patients managed and followed-up in a single gynecologic oncology center due to endometrial cancer, fallopian tube cancer, uterine leiomyosarcoma, and ovarian cancer admitted to the ward because of symptomatic intestinal obstruction. Mean observation time lasted 40.6 months. Non-invasive treatment included fluid therapy, dexamethasone, buscolysin, mebeverine, ranitidine, simethicone, omeprazole, magnesium sulphate, semi-liquid diet, and parenteral nutrition. Characteristics including age, BMI, comorbidities, oncological treatment, histology type, stage, grade, presence of ascites, location of primary tumor and metastases were analyzed.
Results: The number of obstruction episodes varied from 1 to 5. Mean time between multiple episodes lasted 3.2 months. 5 patients required surgical treatment. For the rest of the patients primary non-invasive treatment was sufficient.
Conclusions: Most cases of bowel obstruction in patients with advanced gynecologic malignancies can be successfully managed without invasive treatment. Moreover, non-invasive obstruction management can be applied multiple times in case of recurrence.
Keywords: conservative treatmentintestinal obstructiongynecologic neoplasmsovarian neoplasmspalliative therapysurgical proceduresoperative
References
- Karlin D, Phung P, Pietras C. Palliative care in gynecologic oncology. Curr Opin Obstet Gynecol. 2018; 30(1): 31–43.
- Segev Y, Segev L, Schmidt M, et al. Palliative care in ovarian carcinoma patients-a personalized approach of a team work: a review. Arch Gynecol Obstet. 2017; 296(4): 691–700.
- Bateni SB, Bold RJ, Meyers FJ, et al. Comparison of common risk stratification indices to predict outcomes among stage IV cancer patients with bowel obstruction undergoing surgery. J Surg Oncol. 2018; 117(3): 479–487.
- Down CJ, Kumar L, Singh S, et al. A unique complication of self-expandable metal stent placement in malignant duodenal obstruction. J Surg Case Rep. 2017; 2017(9): rjx169.
- Takao A, Tabata T, Koizumi K, et al. Fracture of a Colonic Self-expandable Metallic Stent in Malignant Colonic Obstruction. Intern Med. 2018; 57(3): 329–332.
- Kucukmetin A, Naik R, Galaal K, et al. Palliative surgery versus medical management for bowel obstruction in ovarian cancer. Cochrane Database Syst Rev. 2010(7): CD007792.
- Mangili G, Aletti G, Frigerio L, et al. Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis. Int J Gynecol Cancer. 2005; 15(5): 830–835.
- Suidan RS, He W, Sun CC, et al. Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer. Int J Gynecol Cancer. 2017; 27(7): 1350–1359.
- Balogun N, Forbes A, Widschwendter M, et al. Noninvasive nutritional management of ovarian cancer patients: beyond intestinal obstruction. Int J Gynecol Cancer. 2012; 22(6): 1089–1095.
- Mantovani G, Macciò A, Massa E, et al. Managing cancer-related anorexia/cachexia. Drugs. 2001; 61(4): 499–514.
- Farias-Eisner R, Kim Y, Berek J. Surgical management of ovarian cancer. Seminars in Surgical Oncology. 1994; 10(4): 268–275.
- Larson J, Podczaski E, Manetta A, et al. Bowel obstruction in patients with ovarian carcinoma: Analysis of prognostic factors. Gynecologic Oncology. 1989; 35(1): 61–65.
- Singer P, Berger MM, Van den Berghe G, et al. ESPEN Guidelines on Parenteral Nutrition: intensive care. Clin Nutr. 2009; 28(4): 387–400.
- Berek JS, Crum C, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2015; 131 Suppl 2: S111–S122.
- Amant F, Mirza MR, Koskas M, et al. Cancer of the corpus uteri. Int J Gynaecol Obstet. 2015; 131 Suppl 2: S96–S104.
- Prat J, Mbatani '. Uterine sarcomas. International Journal of Gynecology & Obstetrics. 2015; 131: S105–S110.
- Bryan DN, Radbod R, Berek JS. An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer. Int J Gynecol Cancer. 2006; 16(1): 125–134.
- Krebs HB, Goplerud DR. Surgical management of bowel obstruction in advanced ovarian carcinoma. Obstet Gynecol. 1983; 61(3): 327–330.
- Furnes B, Svensen R, Helland H, et al. Challenges and outcome of surgery for bowel obstruction in women with gynaecologic cancer. Int J Surg. 2016; 27: 158–164.
- Sartori E, Chiudinelli F, Pasinetti B, et al. Bowel obstruction and survival in patients with advanced ovarian cancer: analysis of prognostic variables. Int J Gynecol Cancer. 2009; 19(1): 54–57.
- Tran E, Spiceland C, Sandhu NP, et al. Malignant Bowel Obstruction in Patients With Recurrent Ovarian Cancer. Am J Hosp Palliat Care. 2016; 33(3): 272–275.
- Bais J, Schilthuis MS, Slors J, et al. Intestinal obstruction in patients with advanced ovarian cancer. Int J Gynecol Cancer. 1995; 5(5): 346–350.
